IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results

/PRNewswire/ --- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the...

Related Keywords

Eilat ,Hadarom ,Israel ,United States ,Zerifin ,Hamerkaz ,American ,Ronen Tsimerman ,Halahmi Sarel ,Eyal Shamir ,Securities Exchange Commission ,Prnewswire Icecure Medical Ltd ,Drug Administration ,Nasdaq ,World Cancer Research Fund International ,Company Annual Report On Form ,Shamir Medical Center ,Urological Association Conference In Eilat ,Nasir Said Of Bnai Zion Medical Center ,Icecure Medical Ltd ,American Cancer Society ,Urological Association Conference ,Cure Medical ,Mass Cryoablation ,Nasir Said ,Bnai Zion Medical ,American Journal ,World Cancer Research Fund ,Chief Executive Officer ,Bnai Zion Medical Center ,Principal Investigator ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,